Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1799 4
1800 1
1802 1
1833 1
1835 3
1844 1
1861 1
1862 1
1865 1
1867 1
1868 3
1869 2
1871 1
1874 2
1877 6
1878 2
1881 3
1882 5
1883 1
1947 1
1948 1
1949 1
1950 2
1951 1
1953 1
1954 2
1957 1
1961 1
1962 1
1964 1
1966 2
1969 3
1970 1
1971 2
1972 3
1973 8
1974 2
1975 4
1976 12
1977 6
1978 10
1979 10
1980 3
1981 5
1982 2
1983 10
1984 9
1985 10
1986 6
1987 9
1988 8
1989 20
1990 20
1991 10
1992 12
1993 9
1994 16
1995 6
1996 26
1997 13
1998 16
1999 11
2000 23
2001 15
2002 20
2003 19
2004 15
2005 16
2006 20
2007 24
2008 21
2009 41
2010 35
2011 30
2012 32
2013 25
2014 31
2015 21
2016 24
2017 33
2018 28
2019 31
2020 53
2021 49
2022 59
2023 62
2024 50
2025 30

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,060 results

Results by year

Filters applied: . Clear all
Page 1
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Sims JR, et al. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.
Trial of Solanezumab in Preclinical Alzheimer's Disease.
Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, van Dyck CH, Iwatsubo T, Marshall GA, Yaari R, Mancini M, Holdridge KC, Case M, Sims JR, Aisen PS; A4 Study Team. Sperling RA, et al. Among authors: sims jr. N Engl J Med. 2023 Sep 21;389(12):1096-1107. doi: 10.1056/NEJMoa2305032. Epub 2023 Jul 17. N Engl J Med. 2023. PMID: 37458272 Free PMC article. Clinical Trial.
Health and Racial Disparity in Breast Cancer.
Yedjou CG, Sims JN, Miele L, Noubissi F, Lowe L, Fonseca DD, Alo RA, Payton M, Tchounwou PB. Yedjou CG, et al. Among authors: sims jn. Adv Exp Med Biol. 2019;1152:31-49. doi: 10.1007/978-3-030-20301-6_3. Adv Exp Med Biol. 2019. PMID: 31456178 Free PMC article. Review.
2020 American College of Rheumatology Guideline for the Management of Gout.
FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, Levy G, Libbey C, Mount D, Pillinger MH, Rosenthal A, Singh JA, Sims JE, Smith BJ, Wenger NS, Bae SS, Danve A, Khanna PP, Kim SC, Lenert A, Poon S, Qasim A, Sehra ST, Sharma TSK, Toprover M, Turgunbaev M, Zeng L, Zhang MA, Turner AS, Neogi T. FitzGerald JD, et al. Among authors: sims je. Arthritis Rheumatol. 2020 Jun;72(6):879-895. doi: 10.1002/art.41247. Epub 2020 May 11. Arthritis Rheumatol. 2020. PMID: 32390306 Free article.
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, Gueorguieva I, Hauck PM, Brooks DA, Mintun MA, Sims JR. Shcherbinin S, et al. Among authors: sims jr. JAMA Neurol. 2022 Oct 1;79(10):1015-1024. doi: 10.1001/jamaneurol.2022.2793. JAMA Neurol. 2022. PMID: 36094645 Free PMC article. Clinical Trial.
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Ramgopal MN, Castagna A, Cazanave C, Diaz-Brito V, Dretler R, Oka S, Osiyemi O, Walmsley S, Sims J, Di Perri G, Sutton K, Sutherland-Phillips D, Berni A, Latham CL, Zhang F, D'Amico R, Pascual Bernáldez M, Van Solingen-Ristea R, Van Eygen V, Patel P, Chounta V, Spreen WR, Garges HP, Smith K, van Wyk J. Ramgopal MN, et al. Among authors: sims j. Lancet HIV. 2023 Sep;10(9):e566-e577. doi: 10.1016/S2352-3018(23)00136-4. Epub 2023 Aug 8. Lancet HIV. 2023. PMID: 37567205 Clinical Trial.
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial.
Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, Collins EC, Sims JR, Mintun MA. Pontecorvo MJ, et al. Among authors: sims jr. JAMA Neurol. 2022 Dec 1;79(12):1250-1259. doi: 10.1001/jamaneurol.2022.3392. JAMA Neurol. 2022. PMID: 36251300 Free PMC article. Clinical Trial.
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.
Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, Zhao Z, Kim J, Kennedy P, Gunasekaran G, Tabrizian P, Doroshow D, Legg M, Hammad A, Magen A, Kamphorst AO, Shareef M, Gupta NT, Deering R, Wang W, Wang F, Thanigaimani P, Mani J, Troncoso L, Tabachnikova A, Chang C, Akturk G, Buckup M, Hamel S, Ioannou G, Hennequin C, Jamal H, Brown H, Bonaccorso A, Labow D, Sarpel U, Rosenbloom T, Sung MW, Kou B, Li S, Jankovic V, James N, Hamon SC, Cheung HK, Sims JS, Miller E, Bhardwaj N, Thurston G, Lowy I, Gnjatic S, Taouli B, Schwartz ME, Merad M. Marron TU, et al. Among authors: sims js. Lancet Gastroenterol Hepatol. 2022 Mar;7(3):219-229. doi: 10.1016/S2468-1253(21)00385-X. Epub 2022 Jan 20. Lancet Gastroenterol Hepatol. 2022. PMID: 35065058 Free PMC article. Clinical Trial.
1,060 results